(1) R LDHA inhibitor FX11 has demonstrated antitumor effects in prostate and breast cancer models. (2) R MCT1/4 inhibitor AZD3965 is being evaluated in a Phase I clinical trial for lymphoma. Here, LDHA is linked to lymphoma.